Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Adma Biologics (ADMA) EBT Margin (2016 - 2025)

Adma Biologics (ADMA) has disclosed EBT Margin for 13 consecutive years, with 44.26% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBT Margin rose 1473.0% year-over-year to 44.26%, compared with a TTM value of 35.8% through Dec 2025, up 632.0%, and an annual FY2025 reading of 35.8%, up 632.0% over the prior year.
  • EBT Margin was 44.26% for Q4 2025 at Adma Biologics, up from 35.4% in the prior quarter.
  • Across five years, EBT Margin topped out at 44.26% in Q4 2025 and bottomed at 132.7% in Q4 2022.
  • Average EBT Margin over 5 years is 16.67%, with a median of 4.13% recorded in 2023.
  • The sharpest move saw EBT Margin surged 15346bps in 2021, then crashed -10269bps in 2022.
  • Year by year, EBT Margin stood at 30.01% in 2021, then plummeted by -342bps to 132.7% in 2022, then surged by 111bps to 14.34% in 2023, then skyrocketed by 106bps to 29.53% in 2024, then surged by 50bps to 44.26% in 2025.
  • Business Quant data shows EBT Margin for ADMA at 44.26% in Q4 2025, 35.4% in Q3 2025, and 32.87% in Q2 2025.